Skip to main content
. Author manuscript; available in PMC: 2012 Oct 31.
Published in final edited form as: Neurosci Lett. 2011 Sep 12;504(3):185–190. doi: 10.1016/j.neulet.2011.09.005

Figure 4. Administration of the EP2-4 agonist misoprostol protects against injury.

Figure 4

(A) Time scale of treatment with misoprostol 50μg/kg or 500 μg/kg before HIE. (B) Representative series of TTC stained coronal sections 24h after HI. (C) Administration of misoprostol significantly decreases infarct volume at a dose of 500μg/kg (*p<0.05; n=23-25 per group). (D) Quantification of percent infarct area at each of the four levels demonstrates a significant decrease in infarct area for 500μg/kg dose (black) but not for 50μg/kg dose (pink) compared to vehicle (blue; 2w ANOVA of vehicle and 500μg/kg †p<0.001). (E) Misoprostol exerts gender-dimorphic pattern of cerebroprotection in male, but not female pups (ANOVA male pups, *p<0.05; §=NS; n=10-13 per group). (F) Misoprostol reduces bEND3 endothelial cell death (ANOVA ‡p<0.0001; post-hoc †p<0.001 for 0.1 and 10 μM).